Condition: Relapsing Multiple Sclerosis · Primary Progressive Multiple Sclerosis · Sponsor: Hoffmann-La Roche
This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Neurology Associates PA | Maitland, Florida, United States | — |
| University of South Florida | Tampa, Florida, United States | — |
| Johns Hopkins Hospital | Baltimore, Maryland, United States | — |
| Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis | Owosso, Michigan, United States | — |
| UC Health Neurology | Dayton, Ohio, United States | — |
| Premier Neurology | Greenville, South Carolina, United States | — |
| Neurology Clinic PC | Cordova, Tennessee, United States | — |
| CEDOES - Diagnóstico e Pesquisa | Vitória, Espírito Santo, Brazil | — |
| Clinica Amo - Assistencia Medica Em Oncologia | Salvador, Estado de Bahia, Brazil | — |
| Fakultni nemocnice u sv. Anny | Brno, Czechia | — |
| Charles University, Medical faculty, Hradec Kralove | Hradec Králové, Czechia | — |
| Nemocnice Jihlava | Jihlava, Czechia | — |
+ 25 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05232825